Health Care [ 12/12 ] | Pharmaceuticals [ 64/74 ]
NYSE | Common Stock
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally.
The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands.
In addition, the company involved in the contract manufacturing business.
It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems.
The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases.
Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jul 30, 24 | 0.60 Decreased by -10.45% | 0.46 Increased by +30.43% |
| May 1, 24 | 0.82 Decreased by -33.33% | 0.52 Increased by +57.69% |
| Jan 30, 24 | 0.10 Decreased by -91.23% | -0.22 Increased by +145.45% |
| Oct 31, 23 | -0.17 Decreased by -109.55% | -0.34 Increased by +50.00% |
| Aug 1, 23 | 0.67 Decreased by -67.16% | 0.57 Increased by +17.54% |
| May 2, 23 | 1.23 Decreased by -26.35% | 0.98 Increased by +25.51% |
| Jan 31, 23 | 1.14 Increased by +5.56% | 1.05 Increased by +8.57% |
| Nov 1, 22 | 1.78 Increased by +32.84% | 1.39 Increased by +28.06% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 17.70 B Increased by +33.78% | 4.46 B Increased by +286.51% | Increased by +25.22% Increased by +239.41% |
| Jun 30, 24 | 13.28 B Increased by +4.31% | 24.00 M Decreased by -98.97% | Increased by +0.18% Decreased by -99.01% |
| Mar 31, 24 | 14.88 B Decreased by -18.61% | 3.12 B Decreased by -43.80% | Increased by +20.94% Decreased by -30.95% |
| Dec 31, 23 | 14.25 B Decreased by -41.34% | -3.34 B Decreased by -166.96% | Decreased by -23.47% Decreased by -214.15% |
| Sep 30, 23 | 13.23 B Decreased by -41.55% | -2.39 B Decreased by -127.81% | Decreased by -18.09% Decreased by -147.58% |
| Jun 30, 23 | 12.73 B Decreased by -54.10% | 2.33 B Decreased by -76.43% | Increased by +18.27% Decreased by -48.65% |
| Mar 31, 23 | 18.28 B Decreased by -28.76% | 5.54 B Decreased by -29.51% | Increased by +30.32% Decreased by -1.06% |
| Dec 31, 22 | 24.29 B Increased by +1.90% | 4.99 B Increased by +47.19% | Increased by +20.56% Increased by +44.45% |